Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform
Erika Della Mina1, Roberto Ciccone1, Francesca Brustia2
1Department Molecular Medicine, University of Pavia, Pavia, Italy.
European Journal of Human Genetics : EJHG
|May 23, 2014
Summary
Next-generation sequencing (NGS) identified causative mutations in 47% of epilepsy patients. Detailed phenotype and familial data were crucial for accurate molecular diagnosis, offering a rapid and cost-effective approach.
Area of Science:
- Genetics
- Neurology
- Molecular Diagnostics
Background:
- Epilepsy diagnosis often requires identifying causative genetic mutations.
- Conventional genetic testing can be time-consuming and expensive.
- Targeted gene panels offer a potential solution for faster molecular diagnosis.
Purpose of the Study:
- To evaluate the diagnostic yield and efficiency of a targeted next-generation sequencing (NGS) panel for epilepsy.
- To determine the feasibility of providing a quick and cost-effective molecular diagnosis for epileptic disorders.
Main Methods:
- Analyzed 67 epilepsy genes using NGS in 19 patients with epileptic disorders and 15 controls.
- Assessed the diagnostic yield and the role of phenotype and familial information in mutation interpretation.
- Calculated turnaround time and cost-effectiveness compared to conventional methods.
Main Results:
- Achieved a diagnostic yield of 47%, identifying likely causative mutations in nine patients.
- Phenotype information was critical for interpreting mutations in most positive cases.
- The protocol required 8-10 weeks with costs comparable to sequencing 1-2 conventional genes.
Conclusions:
- Targeted NGS provides a rapid and cost-effective molecular diagnostic approach for epilepsy.
- Integrating clinical and familial data significantly enhances diagnostic accuracy.
- Benchtop sequencer compatibility offers manageability and faster turnaround times for epilepsy gene analysis.
